Celyad Oncology announces receipt of Nasdaq notice
04 avr. 2023 16h01 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric...
Celyad Oncology appoints Georges Rawadi as its new CEO
24 mars 2023 02h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric...
Celyad Oncology reports full year 2022 financial results and recent business highlights
23 mars 2023 17h01 HE
|
Celyad Oncology SA
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via...
Celyad Oncology to announce full year 2022 financial results and host conference call
17 mars 2023 17h01 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...
Celyad Oncology announces non-cash impairment
15 mars 2023 02h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...
REPEAT -- Celyad Oncology SA - Letter to Shareholders
01 mars 2023 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 01, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the...
Celyad Oncology SA - Letter to Shareholders
28 févr. 2023 11h16 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the...
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
09 févr. 2023 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...
Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook
03 févr. 2023 01h00 HE
|
Celyad Oncology SA
Celyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and...
Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property
21 déc. 2022 01h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of...